http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lee, Jung Il,Park, Hyun Joo,Lee, Jin Woo,Kim, Young Soo,Jeong, Seok,Lee, Don Haeng,Kim, Hyung Gil,Shin, Yong Woon,Kwon, Kye Sook Blackwell Publishing Ltd 2009 Liver international Vol.29 No.2
<P>Abstract</P><P>Background</P><P>Elevated pretreatment alanine aminotransferase (ALT) over two times the upper limit of normal reference range has been accepted as a marker for predicting HBeAg loss and an indicator for initiating antiviral therapy. Recently, several opinions argued that in patients aged over 40 years, the treatment should be started if they have elevated serum hepatitis B virus (HBV) DNA without elevated ALT. However, initiating treatment in these patients might be argued against by the concept that the rate of HBeAg loss depends on the pretreatment ALT.</P><P>Aim</P><P>This study was conducted to investigate the usefulness of pretreatment ALT in predicting HBeAg loss in patients aged over 40 years under lamivudine treatment.</P><P>Methods</P><P>We retrospectively analyzed 820 HBeAg-positive patients treated with lamivudine. The patients with hepatocellular carcinoma at or after initiating the lamivudine treatment and patients with evident liver cirrhosis were excluded. Three hundred fifty-five patients met the criteria and were divided into two groups: ≤40 years of age (Group 1) and >40 years of age (Group 2).</P><P>Results</P><P>Analysis using the Kaplan–Meier method and the log rank test showed that the cumulative rate of HBeAg loss was not different in the two groups. Multivariate modelling indicated that an elevated pretreatment ALT level was a predictor of HBeAg loss in Group 1 (<I>P</I><0.05), whereas it failed to act as a predictor in Group 2.</P><P>Conclusion</P><P>Antiviral therapy might not need to be deferred until the ALT level increases in order to enhance the chance of HbeAg loss in HBV DNA-(+) patients aged over 40 years.</P>
( Hyun Jung Lee ),( Young Joo Jin ),( Jin Woo Lee ),( Hyun Jung Chung ),( Byung Wook Bang ),( Seok Jeong ),( Kye Sook Kwon ),( Don Haeng Lee ),( Hyung Gil Kim ),( Yong Woon Shin ),( Young Soo Kim ) 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background: Patients with liver cirrhosis frequently undergo secondary prophylactic endoscopic band ligation (EVL), and these patients can suffer from EVL with non-sleep endoscopy. Given the impaired metabolism of drugs administered for sedation in cirrhotic patients, we investigated the safety of sleep endoscopy for secondary prophylactic EVL in those patients who had a previous history of variceal bleeding Methods: A total of 59 cases with secondary prophylactic EVL that were performed at our institution between August, 2010 and April, 2013 were consecutively recruited. We compared the frequency of hepatic encephalopathy (HEP) between patients with sleep endoscopy and non-sleep endoscopy. Midazolam was intravenously injected for conscious sedation, and flumazenil was always used as antidote after sleep endoscopy. Results: The median patient`s age was 55 years (range, 29-89 years). The most common causes of liver cirrhosis were hepatitis B virus infection (44.1%) and alcohol (42.4%). Of the 59 cases, 39 (66.1%), 13 (22.0%), and 7 (11.9%) had Child-Tur- Turcotte- Pugh class A, B, and C, respectively. Sleep endoscopy was performed in 52 (88.1%) of the 59 cases [CTP class A (n=35, 67.3%), B (n=13, 25.0%), and C (n=4, 7.7%), respectively], and the remaining 7 (11.9%) underwent non-sleep endoscopy. Median dosage of midazolam was 5 mg (range, 2-10 mg). None of the patients had experienced HEP after sleep endoscopy for secondary prophylactic EVL, and this result was same to those with non-sleep endoscopy. Conclusions: Our data showed that intravenous midazolam may be used safely in cirrhotic patients, even in those with CTP class C undergoing secondary prophylactic EVL for conscious sedation, but large scaled prospective randomized studies should be performed to confirm our results.
( Jin Woo Lee ),( Don Haeng Lee ),( Jung Il Lee ),( Seok Jeong ),( Kye Sook Kwon ),( Hyung Gil Kim ),( Yong Woon Shin ),( Young Soo Kim ),( Mi Sook Choi ),( Si Young Song ) 대한소화기기능성질환·운동학회 2010 Gut and Liver Vol.4 No.1
Background/Aims: Bacterial infection is accepted as a precipitating factor in cholesterol gallstone formation, and recent studies have revealed the presence of Helicobacter species in the hepatobiliary system. We utilized the polymerase chain reaction (PCR) to establish the presence of bacterial DNA, including from Helicobacter species, in gallstones, bile juice, and gallbladder mucosa from patients with gallstones. Methods: At cholecystectomy, 58 gallstones, 48 bile samples, and 46 gallbladder mucosa specimens were obtained and subjected to nested PCR using specific 16S rRNA primers of H. pylori and other bacteria. Bacterial species were identified by DNA sequencing analysis. Bacterial 16S rRNA was detected in 25 out of 36 mixed-cholesterol gallstones, 1 out of 10 pure-cholesterol gallstones, and 9 out of 12 pigmented stones. Furthermore, 16S rDNA sequencing identified Escherichia coli, Pseudomonas, Citrobacter, Klebsiella, and Helicobacter species. Results: Helicobacter DNA was detected in 4 out of 58 gallstones, 6 out of 48 bile samples, and 5 out of 46 gallbladder specimens. Direct sequencing of Helicobacter amplicons confirmed strains of H. pylori in all four gallstones, five out of six bile samples, and three out of five gallbladder specimens. Almost all mixed-cholesterol gallstones appear to harbor bacterial DNA, predominantly E. coli. Conclusions: H. pylori was also found in the biliary system, suggesting that these bacteria are of etiological importance in gallstone formation. (Gut Liver 2010;4:60-67)
( Oh Hyun Lee ),( Hyun Jung Chung ),( Jin Woo Lee ),( Young Joo Jin ),( Byung Wook Bang ),( Seok Jeong ),( Kye Sook Kwon ),( Don Haeng Lee ),( Hyung Kil Kim ),( Yong Woon Shin ),( Young Soo Kim ) 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background/Aim: As increased tumor necrosis factor .alpha TNF-α) inhibitor use for treatment of many disease, reactivation of hepatitis B virus (HBV) is becoming issues. Especially, there was no guideline for isolated anti-HBV core (HBc) IgG positive patients undergoing TNFα inhibitor therapy and to find the evidence of HBV monitoring in these patients. Methods: Patients who had underwent TNFα inhibitor therapy from October 2009 to December 2012 were included in the study. In this patients group, we retrospectively investigated a series of serum aminotransferase levels, HBV serologic status, the type of TNFα inhibitor therapy and concurrent use of hepatotoxic agents. Results: A total 468 patients were received TNFα inhibitor therapy, and 67 patients were positive result of anti-HBc IgG. In these patients, 8 (11.9%) patients were HBsAg-positive, 15 22.4%) were HBsAg negative/HBsAb negative and 39 (58.2%) were HbsAg negative/HbsAb positive before the start of TNFα inhibitor therapy. HBV reactivation occurred to six patients and 5 of 6 patients were HBsAg positive, another one patient was HBsAg negative/HBsAb negative at baseline. One of five HBsAg positive patient was reactivated HBV infection during TNFα inhibitor therapy even though preemptive therapy. The only factor of past history of chronic hepatitis B (CHB) was statistically significant (P<0.05). and there was not occurred HBV-related mortality. Conclusion: HBV reactivation can occur not only HBsAgpositive but also HBsAg-negative/HBcAb-positive patients underwent TNFα inhibitor therapy. It is important to monitor HBV serology during the TNFα therapy in patients with past CHB history and anti-HBc IgG positive.
New Cultivar of Asiatic Hybrid Lily, ‘Black Sun’ with Greyed Purple Color in Flower
이찬구(Chan-Gu Lee),이기환(Ki-Hwan Lee),함수상(Soo-Sang Hahm),경기천(Ki-Cheon Kyung),김운섭(Woon-Seop Kim),홍계완(Kye-Wan Hong),이종원(Jong-Won Lee),최종진(Jong-Jin Choi),이희덕(He-Duck Lee),이은모(Eun-Mo Lee) 한국원예학회 2011 한국원예학회 학술발표요지 Vol.2011 No.5
소아용 대장내시경을 이용한 소장내시경 검사로 진단한 원발 공장 선암종 1예
이충훤 ( Chung Hwon Lee ),김범수 ( Pum Soo Kim ),이정일 ( Jung Il Lee ),정석 ( Seok Jeong ),이진우 ( Jin Woo Lee ),권계숙 ( Kye Sook Kwon ),이돈행 ( Don Haeng Lee ),김형길 ( Hyung Gil Kim ),신용운 ( Yong Woon Shin ),김영수 ( Youn 대한소화기학회 2006 대한소화기학회지 Vol.48 No.5
A 39-year-old man presented with dizziness and melena for 2 months. Abdominal CT scan showed constrictive wall thickening with enhancement and proximal loop dilatation of the jejunum. On endoscopic examination, there was large amount of bile stained fluid in duodenum. Enteroscopy using pediatric colonoscope demonstrated an encircling mass with obstruction approximately 20㎝ distal to the ligament of Treitz. Endoscopic jejunal biopsy showed moderately differentiated adenocarcinoma. Small intestinal adenocarcinoma is uncommonly encountered in clinical practice. Because small intestine is relatively inaccessible via routine endoscopy, diagnosis of small intestinal neoplasm is often delayed for several months after the onset of symptoms. Most of the patients are diagnosed in advanced stage. Therefore, when a small bowel neoplasm is suspected, enteroscopy is the most useful study. If enteroscope is not available, enteroscopy using pediatric colonoscope may permit earlier preoperative diagnosis. We report a case of primary jejunal adenocarcinoma diagnosed by endoscopic biopsy using pediatric colonoscope. (Korean J Gastroenterol 2006;48:365-368)